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http://dx.doi.org/10.1016/j.ccr.2014.03.009SUMMARYRas-related small GTPases play important roles in cancer. However, the roles of RBJ, a representative of the
sixth subfamily of Ras-related small GTPases, in tumorigenesis and tumor progression remain unknown.
Here, we report that RBJ is dysregulated in human gastrointestinal cancers and can promote carcinogenesis
and tumor progression via nuclear entrapment of mitogen-activated protein/extracellular signal-regulated
kinase (ERK) kinase (MEK)1/MEK2 and activation of ERK1/ERK2. Nucleus-localized RBJ interacts with
MEK/ERK and prolongs the duration of MEK/ERK activation. Rbj deficiency abrogates nuclear accumulation
of MEK1/MEK2, attenuates ERK1/ERK2 activation, and impairs AOM/DSS-induced colonic carcinogenesis.
Moreover,Rbj knockdown inhibits growth of established tumors. Our data suggest that RBJmay be an onco-
genic Ras-related small GTPasemediating nuclear accumulation of activeMEK1/MEK2 in tumor progression.INTRODUCTION
TheRas superfamily of small GTPases is divided into fiveprincipal
subfamilies: theRas,Rho,Rab,Arf (ADP-ribosylation factors), and
Ran subfamilies (Karnoub and Weinberg, 2008). Rbj is a recently
identified member of the sixth subfamily of Ras-related small
GTPases, which was cloned by us independently (GenBank No.
AF178983, named as Rabj) and reported by other labs. RBJ is
characterized by the fusion of a small GTPase domain with a
heat shock protein 70 (hsp70)-interacting J domain. Bioinformatic
analysis reveals thatRBJshareshighest sequencehomologywith
Rab proteins in small GTPase domain but represents a distinct
subfamily of Ras-related small GTPases (dos Santos et al.,Significance
TheRas/Raf/mitogen-activated protein/extracellular signal-reg
nase (ERK) signaling pathway is crucial in tumorigenesis an
signaling pathway in sensitivity and resistance of human cance
of RBJ in tumorigenesis remain unknown. We show that nuc
MEK/ERK, maintaining constitutive MEK/ERK activation and
serve as a nuclear anchor forMEK1/MEK2 during tumorigenesi
nuclear entrapment of activeMEK1/MEK2 and activation of ER
the Ras/Raf/MEK/ERK signaling pathway, casting light on this
682 Cancer Cell 25, 682–696, May 12, 2014 ª2014 Elsevier Inc.2012; Elias and Archibald, 2009; Nepomuceno-Silva et al.,
2004; designated asRbj,Rjl, orDnajc27). However, the biological
and functional data for RBJ are absent up to date. Most of the
Ras-related small GTPases are involved in diverse aspects of
tumorigenesis and tumor progression (Karnoub and Weinberg,
2008). Therefore, we hypothesized that RBJmay also be involved
in tumorigenesis and tumor progression.
Among the well-defined Ras signaling pathways, the Raf/
mitogen-activated protein/extracellular signal-regulated kinase
kinase (MEK)/extracellular signal-regulatedkinase (ERK) signaling
cascade has been demonstrated to play important roles in tumor-
igenesis and has been regarded as targets for cancer treatments
(Friday and Adjei, 2005; Kolch, 2005; Luke and Hodi, 2012).ulated kinase kinase (MEK)/extracellular signal-regulated ki-
d tumor progression, and critical questions regarding this
rs to targeted therapy have been raised. However, the roles
leus-localized RBJ is oncogenic and directly interacts with
leading to transformation and tumor progression. RBJ may
s and a potential target for cancer treatments. RBJ-mediated
K1/ERK2may represent an alternative mode for regulation of
targeted pathway in human cancers.
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Nuclear Entrapment of MEK1/MEK2 by RBJ in CancerGain-of-functionmutations ofRas andRaf aswell as the constitu-
tive activation of ERK1/ERK2 andMEK1/MEK2 have been widely
observed in many cancers (Karnoub and Weinberg, 2008; Kolch,
2005). However, the mechanisms for constitutive MEK/ERK acti-
vation incancers havenotbeen fully elucidated.More importantly,
it remains to be determinedwhether or not other unknownmolec-
ular mechanisms exist in modulation of the Ras/Raf/MEK/ERK
signaling pathway, which may cast light on the understanding of
aberrant activation of MEK/ERK in human cancers and possibly
provide an alternative interpretation of clinically raised questions
about targeted therapy.
Herein, we investigated the roles of RBJ in carcinogenesis and
tumor progression by using knockout and transgenic mice/cells
and by using an azoxymethane (AOM)/dextran sodium sulfate
(DSS)-induced colonic carcinogenesis model. Our data suggest
that RBJ is an oncogenic small GTPase required for carcinogen-
esis and tumor progression by mediating the nuclear accumula-
tion of active MEK1/MEK2 and sustained activation of ERK1/
ERK2.
RESULTS
RBJ Is Aberrantly Overexpressed in Human
Gastrointestinal Cancers and Correlates with
Progression of Human Cancers
Rbj mRNA is rarely detected in normal tissues except testis,
ovary, and brain (Figures S1A and S1B available online) but was
frequently detected in a variety of human and mouse tumor cell
lines (Figures S1C and S1D). We prepared the rabbit polyclonal
antibody against recombinant full-length human RBJ that recog-
nized both human and mouse RBJ (93% protein identity) and
tested its application in western blot and immunohistochemistry
(IHC) assays. RBJ protein could be detected abundantly in
mouse testis (Figures S1E and S1F), in SW480 and B16.F10
tumor cells (Figures S1F and S1G), and in AOM/DSS-induced
mouse colonic tumors (Figure S1H). However, the antibody did
not detect RBJ in NIH 3T3 and LoVo cells negative for Rbj
mRNA expression (Figure S1F) and in colonic tumors derived
from Rbj knockout mice (Figure S1H). Moreover, the levels of
RBJ protein were decreased in Rbj-silenced SW480 and
B16.F10 tumor cells (Figures S1F andS1G). These data indicated
that the RBJ antibody is specific and suitable for applications in
both IHC and western blot.
Next, we examined RBJ expression in tissue microarrays of
human gastrointestinal cancers. We found that RBJ protein
was significantly higher in cancer samples than that in adjacent
noncancer samples (R2 cm away from cancer tissues; Figures
1A and 1B) and was mainly detected in cancers with later tu-
mor-node-metastasis (TNM) stages (Figure 1C; Tables S1, S2,
and S3). Moreover, patients with higher expression of RBJ
showed a shorter overall survival time (Figure 1D). The levels
of Rbj mRNA were also significantly higher in cancer tissues
than that in matched noncancer tissues (Figure 1E; Table S4)
and correlated to TNM stages of colorectal cancers (CRCs)
(Figure 1F).
Two CpG islands were predicted in the promoter region of Rbj
(Figure S1I). Because cancer-associated DNA hypomethylation
is as prevalent as cancer-linked hypermethylation (Esteller,
2008), we treated several human cancer cell lines with the DNAmethylation inhibitor 5-aza-20-deoxycytidine (5-Aza-dC) for
48 hr and then found that RBJ expression was increased in hu-
man cancer cells (Figure S1J). These results indicate that aber-
rant overexpression of RBJ may be potentially caused by
abnormal DNA hypomethylation of Rbj promoter.
RBJ Is an Oncogenic Small GTPase that Activates MEK/
ERK and Induces Cell Transformation
RBJ is predicted to be a Ras-related small GTPase that contains
a C-terminal J domain (Figures S2A and S2B) (Nepomuceno-
Silva et al., 2004). Using glutathione S-transferase (GST)-RBJ
fusion protein, we found that RBJ did bind with guanosine
triphosphate (GTP)/guanosine diphosphate (GDP) and possess
GTPase activity (Figures 2A, 2B, S2C, and S2D), and the C-ter-
minal J domain could interact with recombinant heat shock
cognate 70 (Figure S2E). Mutation of serine 30 (Ser30) into Asn
(RBJ-S30N) abrogated the GTP-binding activity: mutation of
His75 into leucine (Leu) (RBJ-H75L) completely abrogated its
GTPase activity, whereas mutation of His75 into glutamine
(Gln) (RBJ-H75Q) that was commonly found in other Ras-related
small GTPases increased its GTPase activity.
To ascertain the roles of RBJ in tumorigenesis, we stably over-
expressed RBJ in NIH 3T3 fibroblasts (RBJ-3T3; Figure S1F).
RBJ overexpression could enhance cell proliferation (Figure 2C)
and induce colony formation of RBJ-3T3 cells on soft agar (Fig-
ure 2D), both of which could be inhibited by MEK/ERK inhibitors.
In vivo, RBJ-3T3 cells could form fibrosarcoma in Balb/c nude
mice (100% of inoculated mice). Although RBJ-S30N could not
induce NIH 3T3 transformation, RBJ-H75L could potently induce
NIH 3T3 transformation (Figure 2D).
We found that RBJ overexpression activated MEK1/MEK2,
ERK1/ERK2, and Elk-1 in NIH 3T3 cells but with no effects on
Akt and NF-kB activation (Figure 2E). In RBJ+ SW480 and HT-
29 CRC cell lines, knockdown of Rbj could inhibit the basal acti-
vation of MEK/ERK (Figure 2E). By luciferase reporter assays,
we found that RBJ could transactivate Elk-1, AP1, and serum
response element (SRE) reporters, but not NF-kB reporters
(data not shown). These data together suggest that RBJ can acti-
vate the MEK/ERK signaling pathway, which may confer to the
oncogenic activities of RBJ.
The promoter region of Rbj may span a 300 to +50 bp re-
gion and potentially contained consensus sequences for bind-
ing with transcription factors (Figure S2F). Overexpression of
constitutively active K-Ras-G12V, BRAF-V600E, MEK1ED (mu-
tation of Ser218 and Ser222 into glutamate [Glu] and aspartic
acid [Asp], respectively), and ERK2, or treatment with various
extracellular stimuli, could robustly transactivate Rbj promoter
in RBJ LoVo cells (Figure S2G). Therefore, Rbj may be
induced after hypomethylation of its promoter and then be up-
regulated by signals that potentially activate MEK/ERK and/or
NF-kB.
Transgenic overexpression of Rbj in mice did not induce the
spontaneous formation of visible neoplasms and did not affect
growth and reproduction of the transgenic mice. However, em-
bryonic day 13.5 (E13.5) mouse embryonic fibroblasts (MEFs)
derived from Rbj and RBJ-H75L transgenic mice showed
enhanced proliferation (Figure 2F) and could form colonies on
soft agar (Figure 2G). The Rbj transgenic MEFs could not
spontaneously form fibrosarcoma in Balb/c nude mice. WhenCancer Cell 25, 682–696, May 12, 2014 ª2014 Elsevier Inc. 683
Figure 1. Aberrant Overexpression of RBJ in Human Gastrointestinal Cancers
(A) Representative IHC for RBJ expression in tissue microarrays. Typical stainings in the red box region were magnified and shown in adjacent rows.
Scale bars, 100 mm.
(legend continued on next page)
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Figure 2. RBJ Is a Small GTPase that
Induces Cell Transformation
(A) GTP-binding assays of RBJ (GST fusion pro-
teins) in the presence or absence of 100 mM
competitors.
(B) GTPase activity assays of RBJ (GST fusion
proteins).
(C and D) Mock- or RBJ-3T3 cells were examined
for proliferation by [3H]thymidine incorporation (C)
or for colony formation capacity (D) in the pres-
ence or absence of inhibitors. Error bars indicate
mean ± SD (n = 3). Representative images of the
formed colonies are shown (scale bars, 100 mm).
Similar results were obtained in three independent
experiments. V, vehicle (DMSO); P, PD98059
(10 mM); U, U0126 (10 mM); ***p < 0.001 (as
compared to Mock-3T3 cells; ANOVA).
(E) Mock- or RBJ-3T3 cells or CRC cells with
stable knockdown of Rbj were examined by
western blot for MEK/ERK activation. Indicated
NIH 3T3 cells were cultured under normal condi-
tions (control), serum starved for 24 hr, and re-
stimulated with 10% fetal calf serum (FCS) or
epidermal growth factor (EGF) for 30 min in the
presence or absence of inhibitors. Ctrl, scrambled
control RNAi; RNAi, Rbj-specific RNAi.
(F and G) MEFs derived from Rbj or RBJ-H75L
transgenic mice were transfected with or without
indicated active K-Ras/BRAF vectors and were
examined for proliferation (F) or colony formation
on soft agar (G). Error bars indicate mean ± SD
(n = 3). Similar results were obtained in three in-
dependent experiments. *p < 0.05; ***p < 0.001
(as compared to WT cells or mock-transfected
cells; ANOVA). IB, immunoblot.
(H) MEFs derived from WT or Rbj transgenic
mice were transiently transfected with active
K-Ras/BRAF vectors, and MEK/ERK activation
was examined by western blot.
See also Figure S2.
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the transforming capacity of RBJ in MEFs was enhanced (Fig-
ure 2G), corresponding to potentiated effects of RBJ
in activating MEK/ERK (Figure 2H). These data indicate that
RBJ may synergize with Ras/Raf in transformation.
Considering that both NIH 3T3 cells and MEFs were negative
for RBJ, we then validated the effects of RBJ in LoVo cells
potentially competent in expression of RBJ after demethylation(B and C) IHC scores for RBJ staining in indicated cancer samples (B) or in cancer samples demonstrating diffe
plots represent the median, the boxes represent the interquartile range, and the whiskers represent the 2.5th a
Mann-Whitney U test). NC, noncancer.
(D) Overall survival of patients with cancer with high (Rmedian H scores) or low (< median H scores) RBJ level
CAC, colon adenocarcinoma; GAC, gastric adenocarcinoma; RAC, rectal adenocarcinoma
(E and F) qRT-PCR assays of RbjmRNA levels in human cancer tissues. The definitions of the box plots are th
test or Mann-Whitney U test).
See also Figure S1 and Tables S1, S2, S3, and S4.
Cancer Cell 25, 682–6(Figure S1J) and B16 melanoma cells
with low RBJ expression (Figure S1F).
We found that RBJ overexpression (Fig-
ure S2H) promotes the cells in formingcolonies on soft agar (Figure S2I) and enhances ERK1/ERK2
activation (Figure S2J).
RBJ Is Required for AOM/DSS-Induced Colonic
Carcinogenesis and Tumor Progression
To test the roles of RBJ in tumorigenesis, we established Rbj/
mice and examined the effects of Rbj deficiency on AOM/DSS-
induced carcinogenesis (Figures S3A–S3C and 3A). Despiterent TNM stages (C). The horizontal lines in the box
nd 97.5th percentiles (Wilcoxon signed rank test or
s. p values were calculated using the log rank test.
e same as that in (B) and (C) (Wilcoxon signed rank
96, May 12, 2014 ª2014 Elsevier Inc. 685
Figure 3. RBJ Is Required for AOM/DSS-Induced Colonic Carcinogenesis
(A) Schema of AOM/DSS treatments.
(B) Representative macroscopic findings of colon tumors (black circles) induced by AOM/DSS.
(C) Incidence of macroscopic tumors induced by AOM/DSS. Error bars indicate mean of three independent experiments (Fisher’s exact test).
(D and E) Number of macroscopic tumors (D) and tumor burden of AOM/DSS-treated mice (E) per colon. Error bars indicate mean (n = 20; Mann-Whitney U test).
Similar results were obtained in three independent experiments.
(F and G) Four hours after intraperitoneal injection of bromodeoxyuridine (BrdU), the tumors were stained for BrdU+ cells by IHC. Representative images are
shown (F), and BrdU+ cells were counted (G). Error bars indicate mean ± SD of five high fields (Fisher’s exact test). Similar results were obtained in three
independent experiments. Scale bars, 100 mm.
(H–J) AOM/DSS-induced colonic tumors in Rbj transgenic mice. (H) Representative macroscopic findings of colon tumors (black circles). (I) Number of
macroscopic tumors per colon. (J) Tumor burden of AOM/DSS-treated transgenic mice. Error bars indicate mean (n = 20). Similar results were obtained in three
independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001 (as compared to WT mice; ANOVA).
(K and L) On indicated days, colons were collected and examined for microscopic pathological aberrations after hematoxylin and eosin staining (H&E) (n = 10).
The horizontal lines in the box plots represent the median, the boxes represent the interquartile range, and the whiskers represent the 2.5th and 97.5th percentiles.
*p < 0.05; **p < 0.01; ***p < 0.001 (as compared to WT mice; ANOVA).
See also Figure S3.
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mice (mainly in the distal colons; Figures 3B and S3D), Rbj
deficiency significantly decreased the incidence (Figure 3C)
and multiplicity (Figure 3D) of colonic tumors. Moreover, the tu-
mor burden (Figure 3E) and proliferation of the colonic epithelial
cells (Figures 3F and 3G) in Rbj/ tumors were significantly
reduced.
Rbj or RBJ-H75L transgenic overexpression significantly
increased the multiplicity (Figures 3H and 3I) and tumor burden
(Figure 3J) of AOM/DSS-induced colonic tumorswhen examined
on day 80. Before the AOM treatment, the lengths of either colon
or crypt were not significantly different between wild-type (WT)
and Rbj transgenic mice (data not shown). However, we found
that the colons of Rbj or RBJ-H75L transgenic mice showed
an accelerated appearance of typical aberrant histology alter-
ations after AOM/DSS induction, including aberrant crypt foci
(ACFs; indicators of preneoplasms) and nonvisible microscopic686 Cancer Cell 25, 682–696, May 12, 2014 ª2014 Elsevier Inc.tumors (adenomas or carcinomas) (Figures S3E, 3K, and 3L).
These data indicate that RBJ may accelerate AOM/DSS-
induced carcinogenesis and promote the progression of colon
tumors.
RBJ Directly Interacts with MEK1/MEK2 and ERK1/
ERK2
To investigate the mechanisms in RBJ-mediated activation of
MEK/ERK, we performed immunoprecipitation assays to deter-
mine potential RBJ-binding partners. We found that RBJ could
be coimmunoprecipitated with MEK1/MEK2 and ERK1/ERK2
in RBJ-3T3 cells (Figure 4A, lanes 3–5) and RBJ+ CRC cells
(lanes 6, 8, and 10). In RBJ+ CRC cells with Rbj knockdown (Fig-
ure 4A, lanes 7, 9, and 11), the levels of coimmunoprecipitated
MEK/ERK by RBJ were eliminated.
By GST pull-down assays, we found that RBJ could directly
interact with WT MEK1/ERK2 as well as dominant-negative
Figure 4. RBJ Interacts with MEK/ERK
(A) Mock- or RBJ-3T3 cells or CRC cells with stable knockdown of Rbjwere examined by western blot for RBJ-MEK/ERK interaction after immunoprecipitations
(IP). Indicated NIH 3T3 cells were cultured under normal conditions (control), serum starved (0.5% FCS) for 24 hr, and restimulated with 10% FCS or EGF for
30 min. WCL, whole-cell lysates.
(B) Indicated GST fusion proteins (full-length RBJ or RBJ mutants) were incubated with indicated recombinant (Rec) WT or mutant MEK1, ERK2 proteins. Then,
GST pull-down assays were performed followed by immunoblotting with MEK1 or ERK2 antibodies.
(C) NIH 3T3 cells stably transfected with HA-tagged RBJ (WT or mutants) vectors were examined for interactions between HA-tagged RBJ (WT or mutants) and
endogenous MEK/ERK after immunoprecipitations.
(D) Alignment of RBJ sequences (N-terminal 21 residues) derived from various species with molecules containing ERK-docking sites.
(E) Schematic of RBJ domains. EDS, ERK-docking sites; JD, J domain.
(F) GST pull-down assays of RBJ (WT or mutants) interaction with recombinant MEK1 or ERK2 in the presence of excessive GDP or GTPgS.
(G) NIH 3T3 cells stably transfected with indicated vectors were examined for RBJ-MEK/ERK interaction by western blot after immunoprecipitations.
(H) Mock- or RBJ-3T3 cells transiently transfected with vectors encoding WT or mutated MEK1/ERK2 were examined for RBJ-MEK/ERK interactions by western
blot after immunoprecipitations.
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minal 18 residues deleted (RBJDN18) failed to pull down ERK2,
whereas RBJ (19–208 aa) without the N-terminal 18 residues
and J domain could pull down MEK1 (Figure 4B). Similar inter-
action patterns between HA-tagged RBJ and endogenous
MEK/ERK were obtained (Figure 4C). Our data indicate that the
N-terminal 18 residues of RBJ may serve as an ERK1/ERK2-
docking site, and the small GTPase domain may be involved in
interaction with MEK1/MEK2 (Figures 4D and 4E).As a small GTPase, RBJ may switch between GTP- and GDP-
bound conformations. We performed GST pull-down assays in
the presence of excessive GDP or GTPgS in vitro (Figure 4F)
and examined the interaction of RBJ mutants with MEK/ERK
(Figure 4G). Our data showed that RBJ interacted with MEK1/
MEK2 in its GTP-bound status (lanes 3 and 5 versus lanes 2, 4,
and 6 in Figure 4F; lane 4 versus lanes 3 and 5 in Figure 4G),
whereas the interaction between RBJ and ERK1/ERK2 was
affected to a minimal degree by the GTP-bound status of RBJ.Cancer Cell 25, 682–696, May 12, 2014 ª2014 Elsevier Inc. 687
Figure 5. Expression of RBJ Is Correlated to Nuclear Accumulation of Active MEK/ERK in Human Gastrointestinal Cancers
(A) Representative IHC images for phospho-MEK1/MEK2 and phospho-ERK1/ERK2 in consecutive tissue microarrays. Scale bars, 100 mm.
(B–E) IHCscores for phospho-MEK1/MEK2 (BandD) andERK1/ERK2 (CandE) in tissues showinghigh (RmedianHscores) or low (<medianHscores)RBJ levels.
(B and C) H scores of overall staining. (D and E) H scores for nuclear staining. The horizontal lines in the box plots represent the median, the boxes represent the
interquartile range, and the whiskers represent the 2.5th and 97.5th percentiles. **p < 0.01; ***p < 0.001 (as compared to RBJlow samples; Mann-Whitney U test).
(F–J) ELISAs of active MEK/ERK in lysates of human CRC samples (F and G), qRT-PCR assays of mRNA levels of potential ERK1/ERK2 targets (H), and ELISAs of
active MEK/ERK in lysates of human CRC samples showing differential RbjmRNA levels and K-Ras/Brafmutation status (I and J). The definitions of the box plots
are the same as that in (B)–(E). ns, not significant; **p < 0.01; ***p < 0.001 (as compared to Rbjlow samples; Mann-Whitney U test).
See also Figure S4.
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dominant-negative MEK/ERK (Figure 4B). To further examine
the effects of MEK/ERK phosphorylation on RBJ-MEK/ERK
interaction, we transiently transfected RBJ-NIH 3T3 cells
with dominant-negative MEK1 or ERK2. We found that the
interaction of RBJ with dominant-negative MEK1 and ERK2
was decreased (lanes 5 and 6 versus lane 4 for MEK1; lanes
9 and 10 versus lane 8 for ERK2; Figure 4H). Considering
the differences between the in vitro and in vivo analytical con-
ditions, we inferred that the interaction between RBJ and
MEK/ERK may require the coincident compartmentalization
in vivo.688 Cancer Cell 25, 682–696, May 12, 2014 ª2014 Elsevier Inc.Expression of RBJ Is Correlated with Nuclear
Accumulation of Active MEK/ERK in Human
Gastrointestinal Cancers
To investigate the relationship between RBJ expression and
MEK/ERK activation, we examined phosphorylated (phospho)
MEK/ERK in human tissue microarrays demonstrating aberrant
expression of RBJ (Figures S4A and 5A). Both phospho-MEK1/
MEK2 and phospho-ERK1/ERK2 were increased in human
gastrointestinal cancers (Figure 5A; Tables S1, S2, and S3). We
found that the levels of active MEK/ERK were significantly
higher in cancer tissues showing higher levels of RBJ (RBJhigh;
H score R median) than those showing lower levels of RBJ
Cancer Cell
Nuclear Entrapment of MEK1/MEK2 by RBJ in Cancer(RBJlow; H score <median) (Figures 5A–5C). Moreover, we found
that the nuclear levels of active MEK/ERK were significantly
higher in RBJhigh tissues than that in RBJlow tissues (Figures 5D
and 5E). These data indicated that the MEK/ERK signaling
pathway was activated in human gastrointestinal cancers, which
correlated with RBJ expression levels. The expression levels
of RBJ were also correlated with that of overall and nuclear
phospho-MEK1/MEK2 and phospho-ERK1/ERK2 (Figures
S4B–S4E).
In another collection of CRC samples, we also analyzed the
levels of Rbj and phospho-MEK/ERK. We found that levels
of MEK/ERK phosphorylation in cancer tissues were higher in
samples with higher Rbj mRNA levels (Figures 5F and 5G). As
further evidence, the mRNA levels of Ccnd1, Egr-1, and Mki67
(encoding Ki67 protein) were higher in tissues with high Rbj
mRNA levels (Figure 5H). These data indicate that aberrant
expression of Rbj may contribute to constitutive activation of
MEK/ERK in human CRC.
We have shown that RBJ could synergize with Ras/Raf in
MEK/ERK activation and transformation (Figures 2G and 2H).
To test this relationship in clinical samples, we examined the
genetic mutations of Ras (K-Ras, H-Ras, and N-Ras), Braf, and
Mek1 genes (Table S4). The mRNA levels of Rbj were not signif-
icantly different between samples with or withoutRas/Brafmuta-
tions (Table S4). However, the levels of phospho-MEK/ERKwere
significantly higher in cancer samples with Ras/Braf mutations
(Table S4). More importantly, we found that the levels of phos-
pho-MEK/ERK were significantly higher in Rbjhigh cancers either
with or without Ras/Brafmutations (Figures 5I and 5J; Table S4).
These data indicate that RBJ may provoke MEK/ERK activation
initiated either by Ras/Braf mutations or by other upstream sig-
nals activating MEK/ERK.
RBJ Is a Nucleus-Localized Small GTPase that Prolongs
Duration of MEK/ERK Activation
Typically, the Ras small GTPases translocate to plasma mem-
brane to mediate activation of Raf and phosphatidylinositol 3-ki-
nase (Hancock et al., 1990; Karnoub and Weinberg, 2008). So,
we examined the localization of RBJ and found that RBJ was
mainly localized in the nucleus (Figure 6A). The N-terminal 18
residues and the middle 5 resides contain typical monopartite
motifs of nuclear localization signal (NLS; Figures S5A, S5B,
and 6B), which may cause constitutive localization of RBJ within
the nucleus.
Thus, we hypothesized that RBJmay serve as a nuclear anchor
forMEK/ERK. As expected, we found that RBJ-3T3 cells showed
elevated nuclear levels of active MEK/ERK (Figure 6C) and pro-
longed nuclear kinase activity of MEK/ERK (Figure 6D). In RBJ+
CRC cells, such as Ras-mutated SW480 cells, Braf-mutated
HT-29 cells, and Caco-2 (WT Ras/Braf) cells, knockdown of Rbj
expression significantly reduced the nuclear phospho-MEK1/
MEK2and total phospho-ERK1/ERK2 (especially 24 hr after stim-
ulation) (Figure 6E). In contrast, Rbj knockdown did not affect the
nuclear presence of active MEK1/MEK2 in RBJ LoVo cells.
To discriminate the relative importance of RBJ-MEK and RBJ-
ERK interaction in activating theMEK/ERK signaling pathway,we
examined the effects of RBJ-S30N (deficient in binding MEK1/
MEK2 but competent in binding with ERK1/ERK2, Figure 4G)
on ERK1/ERK2 activation in RBJ+ CRC cells. RBJ-S30N nega-tively regulated the basal and residual MEK/ERK activation in
RBJ+ CRC cells (Figure 6F). These data indicated that RBJ may
be involved in constitutive activation of MEK/ERK in CRC cells
mainly via prolonging the nuclear entrapment of active MEK1/
MEK2.
It is still unclear how RBJ mediates nuclear accumulation of
MEK1/MEK2 becauseMEK1/MEK2 is characterized by the pres-
ence of nuclear export signal (NES) (Adachi et al., 2000; Burack
and Shaw, 2005; Fukuda et al., 1996, 1997a). We hypothesized
that RBJ may interact with the NES of MEK1/MEK2, thus block-
ing nuclear export of MEK1/MEK2. In NIH 3T3 cells, we found
that RBJ failed to coimmunoprecipitate MEK1 without NES
(MEK1DNES) (Figure 6G), which was further confirmed by GST
pull-down assays in the presence of NES polypeptide (Fig-
ure 6H). Therefore, RBJ entraps MEK1/MEK2 in the nucleus by
interacting with the NES of MEK1/MEK2.
Based on the above data, it may be inferred that RBJ functions
similarly to MEK1 without NES. To test this possibility, we per-
formed ELISAs of phospho-ERK1/ERK2, Elk-1 reporter assays,
and transformation assays. We found that MEK1DNES was
more potent in activation of ERK1/ERK2 and Elk-1 reporters
than WT MEK1 or RBJ, whereas cotransfection of WT MEK1,
but not MEK1DNES, could synergistically potentiate the effects
of RBJ in activating ERK1/ERK2 and Elk-1 reporters (Figures 6I
and 6J). Moreover, dominant-negative MEK1 mutants failed to
provoke RBJ in activating ERK1/ERK2 signaling. We also found
that MEK1 could promote the efficacy of RBJ in transformation
of NIH 3T3 fibroblasts (Figure 6K). Therefore, RBJ may activate
MEK/ERK signaling pathways in a similar manner to MEK1 inca-
pable of exporting from the nucleus, and RBJ-mediated activa-
tion of the MEK/ERK pathway requires the phosphorylation of
MEK1/MEK2.
Rbj Deficiency Blocks Nuclear Accumulation of Active
MEK1/MEK2 in AOM/DSS-Induced Colonic Tumors
To verify that RBJ activates MEK/ERK via nuclear entrapment of
active MEK1/MEK2, we examined the activation status and
localization of active MEK/ERK in AOM/DSS-induced colonic tu-
mors using Rbj/ mice. We found that Rbj deficiency could
significantly decrease the levels of active MEK/ERK as well as
the target Ccnd1 in Rbj/ tumors (Figures 7A–7C). Rbj defi-
ciency significantly reduced the percentages of colonic epithe-
lial cells showing the nuclear presence of active MEK1/MEK2
but not ERK1/ERK2 (Figures 7D and 7E) despite that Rbj
knockout significantly reduced the activation of ERK1/ERK2
in AOM/DSS-induced tumors (Figure 7C). Moreover, we found
that the kinase activities of MEK/ERK were significantly
decreased in Rbj/ tumor cells (Figures 7F and 7G). These
data suggest that RBJ is required for the nuclear presence of
MEK1/MEK2 and activation of MEK/ERK in AOM/DSS-induced
colonic tumors.
Moreover, Rbj deficiency significantly inhibited AOM/DSS-
induced expression of multiple genes in tumors, most of which
were potentially regulated by the MEK/ERK signaling pathway
(Figures S6A and S6B). Quantitative RT-PCR (qRT-PCR) assays
demonstrated that the expression levels of c-fos, Egr-1, Ccnd1,
and Ccne2 were significantly decreased in Rbj/ tumors (Fig-
ure 7H). Therefore, RBJ plays a role in provoking the MEK/ERK
signaling pathway during AOM/DSS-induced carcinogenesis.Cancer Cell 25, 682–696, May 12, 2014 ª2014 Elsevier Inc. 689
Figure 6. The Nucleus-Localized Small GTPase RBJ Serves as a Nuclear Anchor for MEK1/MEK2 and Prolongs the Duration of MEK/ERK
Activation
(A) Indicated cells were stained with BODIPY-BFA (Golgi apparatus, red) and for RBJ (green) and were viewed under confocal microscopy. Scale bars, 100 mm.
(B) NIH 3T3 cells were transfected with indicated HA-tagged RBJ fragments and were stained with anti-HA antibody (green). The nuclei were stained with
Hoechst. Scale bars, 100 mm.
(C and D) Mock- or RBJ-3T3 cells were cultured in 10% FCS (normal), or in 0.5% FCS for 24 hr (0 hr of restimulation) and subsequently treated with 10% FCS or
10 ng/ml EGF for 4 hr (C) or as indicated (D). Then, nuclear fractions were extracted and examined for activeMEK/ERK bywestern blot (C). In (D), nuclear fractions
were subjected to in vitro kinase assays. Immunoprecipitation with immunoglobulin G (IgG) or pretreatment with nuclear export inhibitor leptomycin B (LMB;
10 nM for 30 min) was used as a negative control and a positive control, respectively. Error bars indicate mean ± SD (n = 3). Similar results were obtained in three
independent experiments. ***p < 0.001 (as compared to mock-3T3 cells; two-way ANOVA).
(E) CRC cells with (RNAi) or without (Ctrl) stable Rbj knockdown were cultured in 10% FCS (normal), or in 0.5% FCS for 24 hr and subsequently restimulated (RS)
with 10% FCS as indicated. Active MEK1/MEK2 in the nucleus and ERK1/ERK2 in lysates were determined by ELISA. Error bars indicate mean ± SD (n = 3).
Similar results were obtained in three independent experiments. ns, not significant; ***p < 0.001 (as compared to Ctrl cells; ANOVA).
(F) CRC cells stably transfected with RBJ-S30N were treated and examined as in (E). Error bars indicate mean ± SD (n = 3). Similar results were obtained in three
independent experiments. ns, not significant; ***p < 0.001 (as compared to corresponding Mock cells; ANOVA).
(G) NIH 3T3 cells transiently transfected with indicated vectors were examined for RBJ-MEK1 interaction by immunoblotting after immunoprecipitations.
(legend continued on next page)
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Ras, and Braf) mutations were detected in colonic tumors (9 out
of 28 inRbj+/+ mice and 4 out of 12 inRbj/mice). The volume of
tumors with K-Ras mutations was not larger than that without
K-Ras mutations in Rbj+/+ mice, although the tumors with
K-Ras mutations were larger than that without K-Ras mutations
in Rbj/ mice (Figure S6C). Regardless of K-Ras mutation sta-
tus, Rbj deficiency decreased the tumor volumes. Furthermore,
we found that the levels of phospho-MEK/ERK were decreased
in Rbj/ tumors with or without K-Ras mutations (Figures S6D
and S6E). These data indicate that RBJ is involved in AOM/
DSS-induced tumorigenesis and MEK/ERK activation with or
without K-Ras mutations.
Knockdown of Rbj Inhibits Tumor Progression
To further test the significance of RBJ in tumor development, we
stably silenced the expression of RBJ in six CRC cell lines (Fig-
ure 8A). The MEK/ERK activation, cell proliferation, colony for-
mation on soft agar, and in vivo tumor growth of Rbj-silenced
tumor cells were all significantly inhibited (Figures 8B–8F). More-
over, Rbj-silenced CRC cells were more sensitive to MEK/ERK
inhibitor CI-1040 (PD184352) in cell proliferation (Figure 8D)
and colony formation assays (Figure 8E) as compared to control
RNAi. To exclude the potential off-target effects of Rbj knock-
down, we transiently overexpressed Rbj resistant to small inter-
fering RNAs (siRNAs) (pRe) in Rbj-silenced SW480 cells and
examined cell proliferation, colony formation, and ERK1/ERK2
activation. We found that this Rbj mutant could rescue these
effects of Rbj knockdown on SW480 cells (Figures S7A–S7C).
Similar results were obtained in HT-29 and Caco-2 cells (data
not shown). So, the above-observed effects of RBJ in CRC cells
were attributed to Rbj knockdown.
To investigate the possible application ofRbj knockdown in tu-
mor therapy, we tested the effects of Rbj siRNAs in established
tumors in combination with the selective MEK inhibitor CI-1040
(Sebolt-Leopold et al., 1999). Intratumoral injection of Rbj
siRNAs could potentiate the effects of CI-1040 in inhibiting the
growth of SW480 and HT-29 (Figure 8G) but not LoVo tumors.
Correspondingly, the levels of active MEK/ERK in the tumors
were inhibited by CI-1040 and Rbj knockdown, with the most
significant inhibition of MEK/ERK by the combination of CI-
1040 and Rbj siRNAs (Figure 8H). These data suggest that Rbj
siRNAsmay synergize with CI-1040 in inhibiting MEK/ERK, lead-
ing to tumor regression in vivo.
We then went further to investigate the effects of Rbj knock-
down on tumor progression in immune-competent hosts.
Silence of Rbj expression in RBJhigh CT-26, B16.F10, and 4T1(H) GST pull-down assays of RBJ interaction with recombinant (Rec) MEK1 in the
Akt (2), IkBa (3), p53 (4), and cyclin B1 (5).
(I) Mock- or RBJ-3T3 cells (13 107 cells) were transiently transfected with indicate
Error bars indicate mean ± SD (n = 3). Similar results were obtained in three ind
responding Mock-3T3 cells; ANOVA).
(J) NIH 3T3 cells were transiently transfected with indicated vectors and Elk-1 rep
asmean ± SD (n = 3). Similar results were obtained in three independent experime
ANOVA).
(K) Mock- or RBJ-3T3 cells (1 3 104 cells) were transiently transfected with indic
Error bars indicate mean ± SD (n = 3). Similar results were obtained in three ind
responding Mock-3T3 cells; ANOVA).
See also Figure S5.cells inhibited the cell proliferation, colony formation, as well as
in vivo tumorigenicity (Figures S7D–S7G). Rbj knockdown in es-
tablished tumors could inhibit the growth of these tumors (Fig-
ure S7H). These data suggest that Rbj knockdown inhibits tumor
progression, and RBJ may be a potential therapeutic target for
cancers.
DISCUSSION
Rbj itself was not spontaneously mutated within exons in human
CRC (data not shown). Unlike the observations in human cancers
with gain-of-function mutations of Ras/Raf, Rbj may regulate
tumorigenesis through aberrant overexpression. Searching the
Oncomine (Rhodes et al., 2007) database (gene, Rbj; analysis
type, cancer versus normal analysis; cancer type, gastric cancer
or CRC), we found that increased mRNA levels of Rbj had been
detected in adenomas and advanced cancers, with a larger size
or with a higher pathological grade of human gastric (Chen et al.,
2003b; D’Errico et al., 2009; Takeno et al., 2010) and colorectal
(Gaspar et al., 2008; Hong et al., 2010; Jorissen et al., 2009; Kai-
ser et al., 2007; Sabates-Bellver et al., 2007; Skrzypczak et al.,
2010) samples. However, these data are variable, even with
studies showing the downregulation of Rbj. Similar data were
obtained when we searched the Gene Expression Omnibus
(GEO) database provided by the National Center for Biotech-
nology Information (NCBI). However, our data convincingly
showed that RBJ was aberrantly overexpressed in CRC at
both mRNA and protein levels on the whole. The detection of
higher levels of RBJ expression in TNM stages III–IV versus
stages I–II as well as the potentiation of the MEK/ERK signaling
pathway by RBJ may together suggest that RBJ, unlike Ras in
the early onset of cancer (Johnson et al., 2001), may be an onco-
protein mainly promoting tumor progression at a later stage of
tumorigenesis.
Compartmentalization of ERK1/ERK2 by scaffolding proteins,
such as KSR, with a similar expression to fibroblast growth fac-
tor (FGF) (Sef) and IQGAP1, plays a crucial role in the regulation
of signaling duration, intensity, and specificity of ERK1/ERK2
(Kolch, 2005; Roy et al., 2004; Therrien et al., 1996; Torii
et al., 2004). MEK1/MEK2 is mainly a cytoplasmic protein due
to the NES (Adachi et al., 2000; Burack and Shaw, 2005; Fu-
kuda et al., 1996, 1997a; Jaaro et al., 1997). However, partial
nuclear localization of MEK1/MEK2 in cancers has been
observed by several groups (Duhamel et al., 2012; Gotoh
et al., 1999; Lee et al., 2004; Yao et al., 2001). In mammalian
cells, MEK1/MEK2 can enter the nucleus in the prophase of a
cell cycle and plays a potential role in M phase entry (Gotohpresence of blocking peptide corresponding to the NES (NES BP) of MEK1 (1),
d vectors for 48 hr, and active ERK1/ERK2 in lysates was measured by ELISA.
ependent experiments. ns, not significant; ***p < 0.001 (as compared to cor-
orters for 48 hr. Then, reporter assays were performed, and data are presented
nts. ns, not significant; ***p < 0.001 (as compared to corresponding Mock cells;
ated vectors, and their capacities in colony formation assays were examined.
ependent experiments. ns, not significant; ***p < 0.001 (as compared to cor-
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Figure 7. RBJ Is Required for Nuclear Acti-
vation of MEK/ERK in AOM/DSS-Induced
Colonic Tumors
(A–E) IHC assays for colonic tumors isolated on
day 80 of AOM/DSS induction. The red boxes
represent the magnified typical staining of the
original images (A). Cells with positive staining (B
and C) or nuclear staining (D and E) of phospho-
MEK/ERK were counted. Error bars indicate
mean ± SD of five high fields (Fisher’s exact test).
Representative data of three independent exper-
iments are shown. Scale bars, 100 mm.
(F and G) Fresh colonic tumors derived from WT
(n = 16) or Rbj/ (n = 6) mice were isolated for
colonic tumor cells and prepared for lysates or
nuclear proteins. The kinase activities of MEK/
ERK were then analyzed. The horizontal lines in
the box plots represent the median, the boxes
represent the interquartile range, and thewhiskers
represent the 2.5th and 97.5th percentiles. Similar
results were obtained in three independent ex-
periments. *p < 0.05; **p < 0.01 (Mann-Whitney U
test).
(H) qRT-PCR assays for indicated MEK/ERK tar-
gets in colonic tumors derived fromWT (n = 16) or
Rbj/ (n = 6) mice. Error bars indicate mean ± SD.
Similar results were obtained in three independent
experiments. **p < 0.01; ***p < 0.001 (Mann-
Whitney U test).
See also Figure S6.
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et al., 1999). One report has suggested that Sef downregulation
by Ras may be one potential mechanism for the nuclear pres-
ence of MEK1/MEK2 in CRCs (Duhamel et al., 2012). However,
an apparent hypothesis and more efficient machinery for nu-
clear accumulation of MEK1/MEK2 exist: nuclear-anchoring
proteins blocking nuclear export of MEK1/MEK2. Our study
suggests that RBJ may be the nuclear anchor for MEK1/
MEK2. In human gastrointestinal cancers, we found that
expression levels of RBJ were correlated to nuclear active
MEK1/MEK2 staining. Therefore, RBJ may be the major mole-
cule that serves as the nuclear anchor for MEK1/MEK2,
possibly providing spatiotemporal regulation of ERK1/ERK2 in
the nucleus. The scaffolding roles of RBJ in deregulation of692 Cancer Cell 25, 682–696, May 12, 2014 ª2014 Elsevier Inc.the MEK/ERK signaling can thus be
described as a ‘‘wait and entrap’’ model
(Figure S7I).
Constitutive activation of MEK/ERK
has been detected in about 30% of all
cancers (Karnoub and Weinberg, 2008;
Kolch, 2005) and can induce transforma-
tion (Cowley et al., 1994; Mansour et al.,
1994). Nucleus-localized MEK1/MEK2 is
potent in activation of ERK1/ERK2 and
transformation of fibroblasts (Fukuda
et al., 1997a; Duhamel et al., 2012). Phos-
pho-ERK1/ERK2 is dissociated from
MEK1/MEK2 in the cytoplasm and
entered the nucleus (Burack and Shaw,
2005; Fukuda et al., 1997b). RBJ-medi-ated activation of ERK1/ERK2 may be due to the adaptation of
MEK/ERK together, which facilitates the activation of ERK1/
ERK2 by phospho-MEK1/MEK2. Our data suggest that RBJ
could slowly switch between GTP- and GDP-bound conforma-
tions, and RBJ-MEK1/MEK2 interaction required the GTP-bind-
ing capacity of RBJ. It may be inferred that the RBJ-MEK1/
MEK2 interaction may be stable but not permanently, which per-
mits a dynamic nucleocytoplasmic translocation of MEK1/MEK2
and reactivation of MEK1/MEK2 by upstream kinases in cytosol.
Our data showed that RBJ could promote the activation of MEK/
ERK and transcription of target genes, suggesting that RBJ-
mediated nuclear entrapment of MEK1/MEK2 may not lead to
inhibition of the MEK/ERK signaling pathway but contribute to
constitutive activation of MEK/ERK in human cancers.
Figure 8. Knockdown of Rbj Inhibits Tumor Progression and Increases Sensitivity of Cancer Cells to MEK1/MEK2 Inhibitor CI-1040
(A) Stable knockdown of Rbj expression in human CRC cell lines. RBJ expression was examined by western blot.
(B–F) Indicated human CRC cells were examined for active MEK1/MEK2 in the nucleus (B) and active ERK1/ERK2 in lysates (C) by ELISA, for cell proliferation (D)
and colony formation on soft agar (E), or for in vivo tumor growth (F). CI-1040was used at 5 mMof concentration. Error bars indicatemean ± SD (n = 3 in B–E; n = 10
in F). Similar results were obtained in three independent experiments. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001 (one-way or two-way ANOVA).
(G) When tumor volume reached 70–100 mm3, the established tumors (n = 10) were treated as indicated. Black arrows indicate the episodes of siRNA injections.
Error bars indicate mean ± SD. *p < 0.05; **p < 0.001; ***p < 0.001 (two-way ANOVA).
(H) The day after the last siRNA injection, tumors were excised and isolated for tumor cells. Then, whole-cell lysates were prepared and examined for MEK/ERK
activation status by ELISA. The horizontal lines in the box plots represent the median, the boxes represent the interquartile range, and the whiskers represent the
0–100th percentiles. Similar results were obtained in three independent experiments (n = 5). *p < 0.05; **p < 0.01; ***p < 0.001 (Mann-Whitney U test).
See also Figure S7.
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pathway have been tested in various human cancers (Friday
and Adjei, 2005; Luke and Hodi, 2012). Our data using siRNAs
specific for Rbj in the treatment of established tumors suggestthat Rbj knockdown could inhibit tumor growth and increase
the sensitivity of CRC cells to MEK1/MEK2 inhibitor. Recently,
a peptide corresponding to the ERK1/ERK2-binding domain of
the scaffold protein IQGAP1 inhibited Ras- and Raf-drivenCancer Cell 25, 682–696, May 12, 2014 ª2014 Elsevier Inc. 693
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Nuclear Entrapment of MEK1/MEK2 by RBJ in Cancertumorigenesis and acted as a systemically deliverable therapeu-
tic (Jameson et al., 2013). Peptide blocking the RBJ-MEK/ERK
interaction may be used in cancer therapies in the future. Further
examinations of RBJ-MEK1/MEK2 interaction with the assis-
tance of high-resolution crystal structure studies may help to
design potential drugs in the future.
A common phenomenon in Raf/MEK inhibitor-based therapy
is primary and acquired resistance (Friday and Adjei, 2005;
Luke and Hodi, 2012). Treatment of melanomas with vemurafe-
nib usually associates with a significantly reduced activation
of ERK1/ERK2 but a less-pronounced decrease of phospho-
MEK1/MEK2; failure of the drug to inhibit ERK1/ERK2 is associ-
ated with drug resistance (Bollag et al., 2010; Poulikakos et al.,
2010; Trunzer et al., 2013). Because Rbj knockdown inhibited
ERK1/ERK2 in CRC cells and increased their sensitivity to
CI-1040, Rbj may predict sensitivity to inhibitors in CRC. Upon
vemurafenib treatment, both nuclear and cytoplasmic ERK1/
ERK2 activities were inhibited, whereas decreases in cyto-
plasmic phospho-ERK1/ERK2 correlated better with tumor
response (Bollag et al., 2010). Whether Rbj is involved in vemur-
afenib-induced alteration of ERK1/ERK2 compartmentalization
may need future investigations.
In sum, our study has characterized the roles and potential
mechanisms of the oncogenic small GTPase RBJ in tumorigen-
esis and tumor progression. Our data suggest that RBJ may
serve as a nuclear scaffold for MEK/ERK, thus prolonging
the activation of MEK/ERK. However, roles for the J domain of
RBJ in tumorigenesis may need further investigation. Because
Rbj is preferentially expressed in testis and brain, further investi-
gations are required to reveal the physiological roles of RBJ in
these organs.
EXPERIMENTAL PROCEDURES
Mice
WTC57BL/6 and Balb/c mice and Balb/c nudemice (6–8 weeks old) were pur-
chased from Joint Ventures Sipper BK Experimental Animal. The transgenic
mice for Rbj were established as described (Wang et al., 2009). The knockout
C57BL/6N mice for Rbj were prepared by Lexicon Pharmaceuticals as
described by Hansen et al. (2008). All animal experiments were undertaken
in accordance with the National Institutes of Health Guide for the Care and
Use of Laboratory Animals and with the approval of the Scientific Investigation
Board of Second Military Medical University, Shanghai.
Tumor Samples
All the fresh tumor tissues were excised from patients hospitalized in the
Department of Pathology, Changhai Hospital, SecondMilitary Medical Univer-
sity (Shanghai), or in the Department of Colorectal Surgery, Xinhua Hospital,
Shanghai Jiaotong University School of Medicine (Shanghai) after providing
informed consent. Genomic DNA, total RNA, and tissue lysates were prepared
and stored at80C until analyses. All experiments were undertaken in accor-
dance with the approval of the Scientific Investigation Board of SecondMilitary
Medical University and Shanghai Jiaotong University School of Medicine and
were conducted in accordance with the ethical principles originating from the
Declaration of Helsinki.
RBJ Polyclonal Antibody Preparation
ThepurifiedGST-RBJ fusionproteinwasused to immunize femaleNewZealand
rabbits according to the conventional procedure. The anti-RBJ serum was
purifiedbyusing proteinA affinity chromatography after the serumwaschroma-
tographed through the columns (Pierce) embeddedwithE. coli lysates express-
ing GST-Rab39 (Chen et al., 2003a) and GST-DnaJC9 (Han et al., 2007), aiming
to remove the potential cross-reactivity to GST, Rab small GTPase, and J694 Cancer Cell 25, 682–696, May 12, 2014 ª2014 Elsevier Inc.domain. Specificity and titration of the antibody were examined by western
blot, IHC, and immunofluorescencemicroscopy in cells or tissueswith differen-
tial levels of RBJ.Tissue Microarrays and IHC
Tissue arrays containing multiple human gastrointestinal tissues, including
gastric (HStm-Ade180Sur-01), colon (HCol-Ade180Sur-01), and rectal
(HRec-Ade180Sur-01) adenocarcinomas, were obtained from Shanghai
Outdo Biotech. The EnVision+ detection system (Dako) was used per the man-
ufacturer’s instructions. Immunostained microarrays were scored by multi-
plying the intensity (0–3) and extent (0–100) of staining for each tissue point
as previously described by Bollag et al. (2010).AOM/DSS-Induced Colon Cancer
Colitis-associated CRC was induced as described by Neufert et al. (2007).Isolation and Manipulation of Primary MEFs
The MEFs were isolated from E13.5 embryos, propagated, cultured, and
manipulated as described by Aaronson and Todaro (1968).Statistical Analysis
All the statistical analyses were performed using GraphPad Prism 5.0 soft-
ware. All the experiments were repeated at least three times. Data are
described using mean ± SD. p < 0.05 was considered statistically significant.
For cells and reagents, plasmids, genotyping, qRT-PCR, GTP binding,
GTPase activity assay, IHC scoring method, western blotting, and RNAi,
please see Supplemental Experimental Procedures.ACCESSION NUMBERS
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